Stay updated on Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial
Sign up to get notified when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.

Latest updates to the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page's revision tag was updated from v3.6.3 to v3.6.4. This indicates a small platform or content update rather than a change to study details.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe page now displays a new revision label 'Revision: v3.6.3'. This replaces the previous 'Revision: v3.6.2' and indicates a version update of the page content.SummaryDifference0.1%

- Check36 days agoChange DetectedRevision label on the page footer was updated from v3.6.0 to v3.6.2, indicating a newer platform version. This update does not modify the study details or visible content.SummaryDifference0.1%

- Check51 days agoChange DetectedA recruitment-closed banner is now displayed on the page. New help sections (How to Read a Study Record, Common Questions, How to Join a Study) are added, and a formatting change updates 'Intervention / Treatment' to 'Intervention/Treatment' along with a revision stamp to v3.6.0.SummaryDifference0.4%

- Check58 days agoChange DetectedPage revision tag updated from v3.5.4 to v3.5.5, indicating a maintenance/patch-level update to the page. This change does not alter the visible content or behavior of the page.SummaryDifference0.1%

- Check79 days agoChange DetectedThe page shows a new revision tag, v3.5.4, replacing the previous v3.5.3, indicating a small update to the document version. The change affects metadata only and does not modify study details or results.SummaryDifference0.1%

Stay in the know with updates to Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.